# Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma

> **NCT01139359** · PHASE1 · WITHDRAWN · sponsor: **Alaunos Therapeutics**

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** darinaparsin
- **DRUG:** CHOP

## Key facts

- **NCT ID:** NCT01139359
- **Lead sponsor:** Alaunos Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-06
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study enrollment was withdrawn as it is no longer the sponsor's intention to study this indication under this protocol.
- **Last updated:** 2012-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01139359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01139359, "Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01139359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*